Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||
| DOI | 10.1007/S44164-023-00052-1 | ||
| Año | 2023 | ||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
PurposeHuman induced pluripotent stem cell (hiPSC)-derived lung cell types such as alveolar epithelial cells are promising for toxicological and pharmaceutical in vitro screenings. Reproducible differentiation processes are highly demanded, but protocols which are suitable for the high-throughput generation of lung cell types from hiPSCs are lacking.MethodsIn this study, a new approach for the hiPSC-differentiation in alveolar epithelial-like cells type 2 under dynamic 3D-conditions in a suspension bioreactor is presented. Gene and protein expression analyses of key markers during the embryonal lung development have been performed in comparison to cells differentiated under static 2D-conditions to evaluate the differentiation efficacy of the new bioreactor-based approach. Finally, the resulting cells were infected by SARS-CoV-2 pseudotypes to demonstrate their functionality and suitability for e.g. COVID-19 drug development.ResultsThe dynamic bioreactor is suitable to differentiate hiPSCs in spheroids, which express relevant lung markers in each developmental stage on gene and protein level. The 3D method is able to significantly increase the expression of some markers in comparison to conventional 2D differentiation. 3D-differentiated alveolar epithelial-like cells express functional SARS-CoV-2 receptors and can display the viral infection.ConclusionThe presented dynamic 3D-differentiation is a promising, new approach to generate alveolar epithelial-like cells from hiPSCs as cell source for in vitro lung models.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Mueller, Michelle | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
|
| 2 | Kohl, Yvonne | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
|
| 3 | Germann, Anja | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
|
| 4 | Wagner, Sylvia | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
|
| 5 | Zimmermann, Heiko | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
Saarland Univ - Alemania Universidad Católica del Norte - Chile |
| 6 | von Briesen, Hagen | - |
Fraunhofer Inst Biomed Engn IBMT - Alemania
|
| Fuente |
|---|
| European Union |
| HORIZON EUROPE Marie Sklodowska-Curie Actions |
| Marie Curie Actions (MSCA) |
| Agradecimiento |
|---|
| This project has received funding from the European Union's HORIZON 2020 MSCA-RISE Marie Sk & lstrok;odowska-Curie Research and Innovation Staff Exchange Research Program under grant agreement no. 823981. The authors would like to thank Martina Fuss and Nicole Jost (Fraunhofer IBMT) for the SARS-CoV-2 pseudotype production and HEK293T-ACE2-TMPRSS2 maintenance and Andrea Riedmayer for the assistance with flow cytometry data analysis. |